MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Recs

0
Player Avatar stockrockking (< 20) Submitted: 1/15/2011 3:10:44 PM : Outperform Start Price: $9.91 MNKD Score: -85.01

the fda is in full swing they have a few things to look at but it is going to be approved it will make a diabetics quality of life increase with ease of use also the rapid action of new drug

Featured Broker Partners


Advertisement